Division of Nephrology and Kidney Research Institute, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Front Endocrinol (Lausanne). 2023 Feb 16;14:1137604. doi: 10.3389/fendo.2023.1137604. eCollection 2023.
G protein-coupled receptors (GPCRs), the largest family of transmembrane proteins, regulate a wide array of physiological processes in response to extracellular signals. Although these receptors have proven to be the most successful class of drug targets, their complicated signal transduction pathways (including different effector G proteins and β-arrestins) and mediation by orthosteric ligands often cause difficulties for drug development, such as on- or off-target effects. Interestingly, identification of ligands that engage allosteric binding sites, which are different from classic orthosteric sites, can promote pathway-specific effects in cooperation with orthosteric ligands. Such pharmacological properties of allosteric modulators offer new strategies to design safer GPCR-targeted therapeutics for various diseases. Here, we explore recent structural studies of GPCRs bound to allosteric modulators. Our inspection of all GPCR families reveals recognition mechanisms of allosteric regulation. More importantly, this review highlights the diversity of allosteric sites and presents how allosteric modulators control specific GPCR pathways to provide opportunities for the development of new valuable agents.
G 蛋白偶联受体(GPCRs)是最大的跨膜蛋白家族,可响应细胞外信号调节广泛的生理过程。尽管这些受体已被证明是最成功的药物靶点类,但它们复杂的信号转导途径(包括不同的效应 G 蛋白和β-arrestin)和由变构配体介导的途径,常常给药物开发带来困难,例如脱靶或靶效应。有趣的是,鉴定与经典变构结合位点不同的变构结合配体,与变构配体结合可协同促进特定途径的作用。这种变构调节剂的药理学特性为设计针对各种疾病的更安全的 GPCR 靶向治疗提供了新策略。在这里,我们探讨了与变构调节剂结合的 GPCR 的最新结构研究。我们对所有 GPCR 家族的检查揭示了变构调节的识别机制。更重要的是,本综述强调了变构结合位点的多样性,并展示了变构调节剂如何控制特定的 GPCR 途径,为开发新的有价值的药物提供了机会。